Last reviewed · How we verify
CDC-501
CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation.
CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation. Used for Multiple myeloma (phase 2 development).
At a glance
| Generic name | CDC-501 |
|---|---|
| Sponsor | Celgene |
| Drug class | Cereblon E3 ligase modulator (CRBN modulator) |
| Target | Cereblon (CRBN) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
As a cereblon-binding agent, CDC-501 recruits target proteins to the cereblon E3 ubiquitin ligase complex, leading to their proteasomal degradation. This mechanism is similar to other immunomodulatory drugs (IMiDs) developed by Celgene and is designed to modulate immune function and inhibit proliferation of disease-causing cells.
Approved indications
- Multiple myeloma (phase 2 development)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
Key clinical trials
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (PHASE2)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |